Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
21. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
11-08-2021 |
View |
22. |
ECCT/19/11/06 | Optimize LNG EC An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375 |
Principal Investigator(s) 1. Lucy Chepkurui Koech Site(s) in Kenya KEMRI/WRP Kericho |
19-03-2020 |
View |
23. |
ECCT/21/11/05 | SOLIDARITY TRIAL PLUS An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. loice Ombajo Site(s) in Kenya 1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county) 2. The Nairobi Hospital (Nairobi City county) |
13-01-2022 |
View |
24. |
ECCT/20/04/01 | Solidarity An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kilifi Kemri-Wellcome (Kilifi county) 2. Kenya National Hospital (Nairobi City county) 3. Coast PGH (Mombasa county) 4. The Nairobi Hospital (Nairobi City county) 5. Aga Khan University Hospital (Nairobi City county) 6. Moi Teahing and Referal Hospital (Uasin Gishu county) 7. Kenyatta University teaching research and referal hospital (Kiambu county) |
22-06-2020 |
View |
25. |
ECCT/23/07/04 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Dr. Janet Oyieko Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county) |
28-08-2023 |
View |
26. |
ECCT/23/08/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3. Kombewa CRC (Kisumu county) 4. Kondele Childrens Hospital (Kisumu county) |
18-10-2023 |
View |
27. |
ECCT/23/01/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Ogutu Bernhards Ragama Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county) 4. Kombewa CRC (Kisumu county) |
24-05-2023 |
View |
28. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
29. |
ECCT/23/02/02 | KARISMA An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria) |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya KEMRI-CGHR, |
01-06-2023 |
View |
30. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
28-07-2021 |
View |